Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
339
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 7,984.00 | 149.10 | -1.83% |
CAC 40 | 7,858.83 | 17.53 | -0.22% |
DAX 40 | 22,390.84 | 149.14 | -0.66% |
Dow JONES (US) | 42,225.32 | 235.36 | 0.56% |
FTSE 100 | 8,608.48 | 26.32 | -0.30% |
HKSE | 23,202.53 | 4.31 | -0.02% |
NASDAQ | 17,601.05 | 151.16 | 0.87% |
Nikkei 225 | 35,725.87 | 101.39 | 0.28% |
NZX 50 Index | 12,181.86 | 138.33 | -1.12% |
S&P 500 | 5,670.97 | 37.90 | 0.67% |
S&P/ASX 200 | 7,785.20 | 149.30 | -1.88% |
SSE Composite Index | 3,350.13 | 1.69 | 0.05% |